Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate

IL-12 is a potent immune-activating cytokine whose clinical use in solid tumors has been limited by severe systemic toxicity. The authors engineered a novel, reversible antibody format that conditionally activates IL-12 only where the tumor matrix antigen Fibronectin-EDB (FN-EDB) is present. The design pairs a dual-specificity “switch arm” (which competitively binds either tethered IL-12 or FN-EDB, keeping IL-12 masked in circulation) with an FN-EDB “targeting arm” that drives avidity-based binding in the tumor to unveil IL-12. A quantitative systems pharmacology (QSP) model was used to define the binding parameters needed for tumor-selective activity and to project an improved therapeutic window versus clinically tested IL-12 molecules. Phage display and rational, machine-learning-guided library design generated switch binders (Switch1 and Switch2) with the target profiles, and in vitro ELISA and IFN-gamma release assays confirmed FN-EDB-dependent IL-12 unmasking. These functional data were fed back into the QSP model to further refine and expand the predicted therapeutic index. This is described as the first demonstration of a reversible trans-activation logic gate for tumor-conditional cytokine delivery.